In order to provide our clients with the most comprehensive service offer, ABL has developed partnerships with targeted companies and institutes. Developing our panel of technologies and solutions, offering more preclinical models and strengthening our geographical presence are our key partnering drivers. We invite you to discover some of our partners and their domains of expertise.
MabDesign is an organization dedicated to the creation of a unique environment that allows the economic development and growth of the French industrial sector in the field of therapeutic antibodies and immunotherapies.
MabDesign aims to structure the French sector by promoting networking and support the stakeholder’s skills development. To attain this goal, MabDesign is deploying several actions:
- Build and implement a unique nationwide directory of antibody stakeholders allowing the identification of expertise and potential partners.
- Mobilize and support a scientific and industrial network through regular conferences and workshops, thus promoting innovation and networking between high-profile experts.
- Provide access to innovative and dedicated technological and scientific training solutions and skills development support according to the sector requirements.
The SFR Biosciences (UMS3444/US8) develops a strong science and technology policy for the research centers of the Charles Merieux campus in the field of biological sciences.Today this structure brings together researchers from 8 contributing centers dedicated to research in the following major fields of biology: Infectious diseases, Cell biology, Plant biology, Protein biochemistry, Bioinformatics, Structural biology, Molecular evolution, Genomics, Immunology, Microbiology.
ABL and the SFR's Cytometry Platform have signed a partnership to provide state-of-the-art equipment, including the Helios Mass Cytometry system that measures more than 40 parameters simultaneously!
For more information, contact us at email@example.com
As a Cluster, Lyonbiopole is the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region.
It’s supporting ambitious projects and innovative companies in the healthcare & life sciences’ sector. Its aim is to help innovators develop new technologies, products and services in a push toward a more personalized medicine and better treatments for patients.
Created in April 2012 by the Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government, BIOASTER Technological Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to fight antimicrobials resistance, improve vaccines safety and efficacy, quickly diagnose infections at patient bedside and take full advantage of human and animal microbiota.
In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups that rely on t support of the French Government through the "Investissements d'Avenir" , infrastructures funded by regional authorities (Lyon Metropolis and the Auvergne-Rhône-Alpes Region), world-class academics and industries : (the Institute Pasteur, CEA, CNRS, Inserm, Danone Nutricia Research, Institut Mérieux and Sanofi Pasteur) and from highly dynamic SMEs and regional cluster.
With more than 120 collaborators, coming equally from industries & academics, of which the large majority are scientists and engineers originating from 17 different citizenships, BIOASTER drive new technologies innovation in its own infrastructures with state of the art equipment (almost 4,500 m2 split between Lyon and Paris, of which 2,500 m2 is laboratory space) and privilege access to the CNRS-CC-IN2P3 (Centre de Calcul de l’Institut National de Physique Nucléaire et de Physique des Particules : -French National Institute of Nuclear and Particle Physics Computing Centre-) and the Jean Mérieux BSL4 laboratory in Lyon.
L’AFSSI, l’Association Française des Sociétés de Services et d’Innovation pour les Sciences de la Vie est née en 2012 de la volonté de fédérer les sociétés françaises de services et d’innovation technologique dans le domaine stratégique des Sciences du Vivant.
Une large représentation sectorielle en Santé
L’AFSSI vise à regrouper tous les secteurs de la biotechnologie, chimie, environnement, cosmétologie, agroalimentaire, bioinformatique, et inclut le diagnostic et les essais cliniques.
Animateurs clés du développement des sciences du vivant, les entrepreneurs porteurs de projets matures se sont organisés pour une meilleure prise en considération de leurs problématiques de croissance afin que la filière et ses membres, dans leur ensemble, gagnent en ampleur et en compétitivité. L’AFSSI vient compléter la représentation des acteurs dans l’écosystème des Sciences de la Vie.